

29 Jun (SAT) 2024

Venue	Room 305	Room 304	
Time	Registration 07:30-16:00		
07:30-08:00			
08:00-08:25	Plenary Session (I) <i>Epidemiology</i>	Plenary Session (II) <i>Mechanisms of disease progression</i>	
08:25-08:50			
08:50-09:15			
09:15-09:40			
09:40-10:00	Break		
10:00-10:25	Plenary Session (III) <i>Diagnosis</i>	Plenary Session (IV) <i>Metabolic characteristics for MAFLD development</i>	
10:25-10:50			
10:50-11:15			
11:15-11:40			
11:40-12:00	Opening Ceremony		
12:00-12:30	Keynote Lecture (I)		
12:30-13:30	Luncheon Symposium (I) Glied	Luncheon Symposium (II) Roche	
13:30-13:55	Plenary Session (V) <i>Update of HBV treatment</i>	Plenary Session (VI) <i>HCV treatment and long term outcomes</i>	
13:55-14:20			
14:20-14:45			
14:45-15:10			
15:10-15:30	Break		
15:30-16:00	Keynote Lecture (II)		
16:00-16:30	State-of-Art Lecture		
16:30-17:00	Chairman Lecture		
17:00-18:00	Evening Symposium (III) BMS	Evening Symposium (IV) Glied [304A]	Evening Symposium (V) Novo Nordisk [304B]

Plenary Session (I): Epidemiology				Room 305
Moderators: Hwai-I Yang (Taipei) / TBA				
08:00-08:25	PS1-1	<b>Epidemiology of MAFLD: Global and Western Perspectives</b>	Mindie H. Nguyen	San Francisco
08:25-08:50	PS1-2	<b>Epidemiology of MAFLD: Asia-Pacific Perspectives</b>	Mei-Hsuan Lee	Taipei
08:50-09:15	PS1-3	<b>Clinical Outcomes of Patients with MAFLD</b>	Takumi Kawaguchi	Fukuoka
09:15-09:40	PS1-4	<b>MAFLD in Adolescents: A Challenging Global Health Issue</b>	Yen-Hsuan Ni	Taipei

Plenary Session (II): Mechanisms of disease progression				Room 304
Moderators: Chau-Ting Yeh (Taoyuan) / Kathleen E Corey (Boston)				
08:00-08:25	PS2-1	<b>Genetic and Proteomic Architecture Predisposing to Fatty Liver Disease</b>	Mohammed Eslam	Sydney
08:25-08:50	PS2-2	<b>Multi-organ Crosstalk as Pathogenic Mechanism of Fatty Liver Disease</b>	Ying-Ying Yang	Taipei
08:50-09:15	PS2-3	<b>Deciphering Gut Microbiome Signatures for MAFLD</b>	Jun Yu	Hong Kong
09:15-09:40	PS2-4	<b>Vascular Mechanobiology in Fatty Liver Disease</b>	Jordi Gracia Sancho	Barcelona

Plenary Session (III): Diagnosis				Room 305
Moderators: Shiu-Feng Huang (Miaoli) / George Lau (Hong Kong)				
10:00-10:25	PS3-1	<b>Serum-based Biomarkers</b>	TBA	
10:25-10:50	PS3-2	<b>Imaging-based Non-invasive Methods for MAFLD</b>	Terry Yip	Hong Kong
10:50-11:15	PS3-3	<b>Clinical Care Pathway for Risk Stratification</b>	Tawesak Tanwandee	Bangkok
11:15-11:40	PS3-4	<b>Clinical-pathological Correlation of MAFLD/NASH</b>	Matthew Yeh	Seattle

**June 29, 2024 (Saturday)**

**Kaohsiung Exhibition Center**

**Plenary Session (IV): Metabolic characteristics for MAFLD development** Room 304

**Moderators: Cheng-Yuan Peng (Taichung) / David E Cohen (Boston)**

10:00-10:25	PS4-1	<b>The Impact of Insulin Resistance on Disease Initiation</b>	<b>Norbert Stefan</b>	<b>Tübingen</b>
10:25-10:50	PS4-2	<b>Metabolic Alterations from Steatosis to Fibrosis</b>	<b>Ming-Lun Yeh</b>	<b>Kaohsiung</b>
10:50-11:15	PS4-3	<b>Surveillance Program and Patient Management for Cardiovascular Events in MAFLD</b>	<b>Grace Lai-Hung Wong</b>	<b>Hong Kong</b>
11:15-11:40	PS4-4	<b>Therapeutic Approach of Obesity in MASLD Patients</b>	<b>Stephen Harrison</b>	<b>San Antonio</b>

**Opening Ceremony** Room 305

**11:40-12:00**

**Keynote Lecture (I)** Room 305

**Moderator: Wan-Long Chuang (Kaohsiung)**

12:00-12:30	KL1	<b>Emerging Metabolic Therapies for the Management of Patients with NASH</b>	<b>Stephen Harrison</b>	<b>San Antonio</b>
-------------	-----	--	-------------------------	--------------------

**Plenary Session (V): Update of HBV treatment** Room 305

**Moderators: Yun-Fan Liaw (Taipei) / Mindie H. Nguyen (Palo Alto)**

13:30-13:55	PS5-1	<b>Hepatic Steatosis and HBV Infection: Things Beyond the Causal Relationship</b>	<b>Chun-Jen Liu</b>	<b>Taipei</b>
13:55-14:20	PS5-2	<b>HDV: Old Challenges and New Chances</b>	<b>Jin-Lin Hou</b>	<b>Guangzhou</b>
14:20-14:45	PS5-3	<b>CHB Patients of the Gray Zone: To Treat or to Wait</b>	<b>Young-Suk Lim</b>	<b>Seoul</b>
14:45-15:10	PS5-4	<b>The New Hope for HBV Cure</b>	<b>Hung-Chih Yang</b>	<b>Taipei</b>

**June 29, 2024 (Saturday)**

**Kaohsiung Exhibition Center**

**Plenary Session (VI): HCV treatment and long-term outcomes** **Room 304**

**Moderators: Chien-Hung Chen (Kaohsiung) / TBA**

13:30-13:55	PS6-1	<b>HCV Infection and Insulin Resistance: The Linkage Between the Mutual Interaction</b>	<b>Chao-Hung Hung</b>	<b>Taipei</b>
13:55-14:20	PS6-2	<b>Metabolic Impact on Hepatic Outcomes after SVR of HCV Infection</b>	<b>Chen-Hua Liu</b>	<b>Taipei</b>
14:20-14:45	PS6-3	<b>Host Immune Surveillance and Epigenetic Aspects for HCC Development after SVR</b>	<b>Meital Gal-Tanamy</b>	<b>Zfat</b>
14:45-15:10	PS6-4	<b>HCV Microelimination and Metabolic Alternation in the SVR Era</b>	<b>Chung-Feng Huang</b>	<b>Kaohsiung</b>

**Keynote Lecture (II)** **Room 305**

**Moderator: Jia-Horng Kao (Taipei)**

15:30-16:00	KL2	<b>Research priority to advance public health responses to fatty liver disease</b>	<b>Jacob George</b>	<b>Sydney</b>
-------------	-----	--	---------------------	---------------

**State-of-Art Lecture** **Room 305**

**Moderator: Ming-Lung Yu (Kaohsiung)**

16:00-16:30	SL1	<b>National Strategy for Eliminating Liver Diseases: From Communicable to Noncommunicable Hepatitis</b>	<b>Chen-Jen Chen</b>	<b>Taipei</b>
-------------	-----	---	----------------------	---------------

**Chairman Lecture** **Room 305**

**Moderator: Pei-Jer Chen (Taipei)**

16:30-17:00	CL1	<b>TBA</b>	<b>Ming-Lung Yu</b>	<b>Kaohsiung</b>
-------------	-----	------------	---------------------	------------------